Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
- DOI
- 10.1016/s1470-2045(21)00139-x
- Published
- 2021 Jun
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-21-00139-x,
title = {Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.},
author = {Caimi PF and Ai W and Alderuccio JP and Ardeshna KM and Hamadani M and Hess B and Kahl BS and Radford J and Solh M and Stathis A and Zinzani PL and Havenith K and Feingold J and He S and Qin Y and Ungar D and Zhang X and Carlo-Stella C},
year = {2021},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(21)00139-x},
url = {https://doi.org/10.1016/s1470-2045(21)00139-x}
}RIS
TY - JOUR TI - Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. AU - Caimi PF AU - Ai W AU - Alderuccio JP AU - Ardeshna KM AU - Hamadani M AU - Hess B AU - Kahl BS AU - Radford J AU - Solh M AU - Stathis A AU - Zinzani PL AU - Havenith K AU - Feingold J AU - He S AU - Qin Y AU - Ungar D AU - Zhang X AU - Carlo-Stella C PY - 2021 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(21)00139-x UR - https://doi.org/10.1016/s1470-2045(21)00139-x ER -
APA
PF, C., W, A., JP, A., KM, A., M, H., B, H., BS, K., J, R., M, S., A, S., PL, Z., K, H., J, F., S, H., Y, Q., D, U., X, Z., & C, C. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(21)00139-x
Source records
- pubmed · retrieved 2026-09-26T11:30:10.946Z